Triple antithrombotic therapy in patients with atrial fibrillation undergoing PCI: current evidence and practice

References

• McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of patients with atrial fibrillation. Circ J. 2012;126:143–146.
   Google Scholar
• Haim M, Hoshen M, Reges O, et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporarycohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4(1):e001486.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Famingham study. Stroke. 1991;22:983–988.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Bueno H, Byrne R, et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39:213–254.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423–2434.
   PubMed Web of Science ®Google Scholar
• Hamon M, Lemesle G, Tricot O, et al. Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease. J Am Coll Cardiol. 2014;64:1430–1436.
   PubMed Web of Science ®Google Scholar
• Qamar A, Bhatt DL. Stroke prevention in atrial fibrillation in patients with chronic kidney disease. Circ J. 2016;133:1512–1515.
   Google Scholar
• Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a North American perspective-2016 update. Circ Cardiovasc Interv. 2016;9(11):e004395.
   PubMed Web of Science ®Google Scholar
• Paikin JS, Wright DS, Crowther MA, et al. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circ J. 2010;121:2067–2070.
   Google Scholar
• Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170:1433–1441.
   PubMed Web of Science ®Google Scholar
• Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998;339:1665–1671.
   PubMed Web of Science ®Google Scholar
• ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with Irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903–1912.
   PubMed Web of Science ®Google Scholar
• Lip GY, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35(45):3155–3179.
   PubMed Web of Science ®Google Scholar
• Dzeshka MS, Brown RA, Capodanno D, et al. Antiplatelet and antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. InterventCardiol Clin. 2017;6:91–117.
   Google Scholar
• Hess CN, Peterson ED, Peng SA, et al. Use and outcomes of triple therapy among older patients with acute myocardial infarction and atrial fibrillation. J Am Coll Cardiol. 2015;66:616–627.
   PubMed Web of Science ®Google Scholar
• Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) . Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–2619.
   PubMed Web of Science ®Google Scholar
• Kirchoff P, Benussi S, Kotecha D, et al. ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;38:2893–2962.
   Google Scholar
• Rohla M, Weiss TW, Wotja J, et al. Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel. Eur Heart J -Cardiovasc Pharmacother. 2015;1:191–197.
   PubMed Web of Science ®Google Scholar
• Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107–1115.
   PubMed Web of Science ®Google Scholar
• Lamberts M, Gislason GH, Olesen J, et al. Anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll. 2013;92:981–989.
   Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–962.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Mehran R, Bode C, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015;169:472–478.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Gropper S, Bhatt DL, et al. Design and rationale of the RE-DUAL PCI trial: a prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonvalvular atrial fibrillation who have undergone percutaneous coronary intervention with stenting. Clin Cardiol. 2016;39(10):555–564.
   PubMed Web of Science ®Google Scholar
• Macle L, Cairns J, Leblanc K, et al. Review 2016 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. CCS Atrial Fibrillation Guidelines Committee. Can J Cardiol. 2016;32(10):1170–1185.
   PubMed Web of Science ®Google Scholar
• Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol. 2015;65:1619–1629.
   PubMed Web of Science ®Google Scholar
• Dubois V, Dincq AS, Douxfils J, et al. Perioperative management of patients on direct oral anticoagulants. Thrombosis Journal. 2017;15:1–17.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
   PubMed Web of Science ®Google Scholar
• Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circ J. 2013;127(5):634–640.
   Google Scholar
• Verlinden NJ, Coons JC, Iasella CJ, et al. Triple antithrombotic therapy with aspirin, P2Y12 Inhibitor, and warfarin after percutaneous coronary intervention: an evaluation of prasugrel or ticagrelor versus clopidogrel. J Cardiovasc Pharm T. 2017;22(6):546–551.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. PLATO investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–2015.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
   PubMed Web of Science ®Google Scholar
• Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23;363(26):2499–2510.
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. JThorac Cardiovasc Surg. 2016 Nov;152(5):1243–1275.
   Google Scholar
• Siller-Matula JM, Jilma B, Schrör K, et al. Review effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J ThrombHaemost. 2010;8(12):2624–2641.
   PubMed Web of Science ®Google Scholar
• Esteve-Pastor MA, Rivera-Caravaca JM, Shantsila A, et al. Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED score. The AMADEUS trial. ThrombHaemost. 2017;117(12):2261–2266.
   Google Scholar
• Kiviniemi T, Puurunen M, Schlitt A, et al. Bare-metal vs. drug-eluting stents in patients with atrial fibrillation undergoing percutaneous coronary intervention. Circ J. 2014;78(11):2674–2681.
   PubMed Web of Science ®Google Scholar
• Vora A, Puurunen M, Schlitt A, et al. Selection of Stent type in patients with atrial fibrillation presenting with acute myocardial infarction: an analysis from the ACTION (Acute coronary treatment and intervention outcomes network) registry—get with the guidelines. J Am Heart Assoc. 2017;6(8).
   Web of Science ®Google Scholar
• Urban P, Meredith IT, Abizaid A, et al. LEADERS FREE Investigators. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373:2038–2047.
   PubMed Web of Science ®Google Scholar
• Ariotti S, Adamo M, Costa F, et al. Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention?: a pre-specified analysis from the ZEUS trial. JACC Cardiovasc Interv. 2016;9:426–436.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Patialiakas A, Thury A, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015;65:805–815.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.
   PubMed Web of Science ®Google Scholar
• Mahajan R, Brooks AG, Sullivan T, et al. Importance of the underlying substrate in determining thrombus location in atrial fibrillation: implications for left atrial appendage closure. Heart. 2012;98:1120–1126.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 2012;33:2719–2747.
   PubMed Web of Science ®Google Scholar
• Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (watchman left atrial appendage system for embolic protection in patients with atrial fibrillation) trial. Circ J. 2013;127:720–729.
   Google Scholar